Abstracts Archive - Page 1494 of 2607 - ACR Meeting Abstracts

Abstract Number: 1601 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Non-Adherence Is Associated with Higher Sledai Scores in a Predominantly Hispanic Population
Alexandra Perel-Winkler¹, Kayla Neville¹, James Miceli¹, Samantha Nguyen¹, Miya Okado¹, Laura Geraldino-Pardilla¹, Teja Kapoor¹, Jon T. Giles² and Anca Askanase¹, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Non-adherence to medication has been shown to impact mortality, morbidity, and health care utilization in SLE and ranges from 40-80% depending on the methods…
Abstract Number: 1602 • 2017 ACR/ARHP Annual Meeting
Fatigue in Systemic Lupus: The Role of Disease Activity and Its Mediators
Desiree R Azizoddin¹, Meenakshi Jolly², Joel A. Block³ and Perry M. Nicassio⁴, ¹Department of Medicine and Behavioral Sciences, Rush University, Chicago, IL, ²Rush, Chicago, IL, ³Division of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Cousins Center for PNI, UCLA, LA, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that leads to a variety of negative health outcomes. Though treatment continues to advance, fatigue…
Abstract Number: 1603 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Can We Relax the Definition and Still Achieve Low Risk of SLE-Related Damage?
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus low disease activity state (LLDAS) is a systemic lupus erythematosus (SLE) outcome measure that combines low disease activity and a 7.5 mg limit…
Abstract Number: 1604 • 2017 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman² and Laurence S Magder^3,4, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public Health, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
Abstract Number: 1605 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State Protects Against Most Subtypes of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: In SLE the most common types of organ damage are osteoporotic fractures and cataracts. Other types of organ damage, such as end stage renal…
Abstract Number: 1606 • 2017 ACR/ARHP Annual Meeting
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Sasha Bernatsky¹, Murray Urowitz², John G Hanly³, Ann E. Clarke⁴, Marvin J. Fritzler⁵, Caroline Gordon⁶, Juanita Romero-Diaz⁷, Graciela S. Alarcón⁸, Sang-Cheol Bae⁹, Michelle Petri¹⁰, Joan T. Merrill¹¹, Daniel J. Wallace¹², Paul R. Fortin¹³, Dafna D Gladman¹⁴, David A. Isenberg¹⁵, Anisur Rahman¹⁶, Susan Manzi¹⁷, Ola Nived¹⁸, Gunnar K. Sturfelt¹⁹, Christine A. Peschken²⁰, Jorge Sanchez-Guerrero²¹, Guillermo Ruiz-Irastorza²², Cynthia Aranow²³, Ronald F van Vollenhoven²⁴, Asad Zoma²⁵, Kristján Steinsson²⁶, Munther A Khamashta²⁷, Ellen M. Ginzler²⁸, Anca Askanase²⁹, Kenneth C. Kalunian³⁰, Mary Anne Dooley³¹, S. Sam Lim³², Diane L. Kamen³³, Søren Jacobsen³⁴, Manuel Ramos-Casals³⁵, Murat Inanc³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹⁰Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, ¹³Université Laval, CHU de Québec, Québec, QC, Canada, ¹⁴Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁶Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁷Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁸Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁰RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²¹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ²²Biocruces Health Research Institute, Barakaldo, Spain, ²³Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²⁴AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁵University of Glasgow, Glaskow, United Kingdom, ²⁶Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁷Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁸Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³¹UNC Kidney Centre, Chapel Hill, NC, ³²Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³⁵Hospital Clinic, Barcelona, Spain, ³⁶Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: We assessed incident cancers in a large inception SLE cohort, and examined demographic and clinical factors, including tumor-related autoantibodies against proliferating cell nuclear antigen…
Abstract Number: 1607 • 2017 ACR/ARHP Annual Meeting
Tumor-Related Autoantibodies and Cancers in SLE: A Case-Control Study from a Single Centre
Sasha Bernatsky¹, Ann E. Clarke², Joyce Rauch³, Christian Pineau⁴, Evelyne Vinet⁵ and Marvin J. Fritzler⁶, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Patients with systemic lupus (SLE) have altered cancer profiles compared to the general population, with a higher risk of some cancers (e.g. lymphoma) and…
Abstract Number: 1608 • 2017 ACR/ARHP Annual Meeting
Entheseal Involvement in Systemic Lupus Erythematosus: An Ultrasound Study
Andrea Di Matteo¹, Emilio Filippucci², Edoardo Cipolletta², Valentina Lato², Jana Hurnakova^3,4, Iulia Satulu⁵, Rossella De Angelis² and Walter Grassi², ¹Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, ²Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, ³1st Faculty of Medicine, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ⁴University Hospital Motol, Department of Pediatric and Adult Rheumatology, Prague, Czech Republic, ⁵Rheumatology Department, Internal Medicine Clinic, Kalmar County Hospital, kalmar, Sweden
Background/Purpose: A recent study revealed ultrasound (US) findings indicative of entheseal involvement in a small group of patients with systemic lupus erytemathosus (SLE), raising the…
Abstract Number: 1609 • 2017 ACR/ARHP Annual Meeting
Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Nathan Stein¹, Joseph F. Solus¹, Annette M. Oeser¹, Paolo Raggi², C Michael Stein¹ and Michelle J. Ormseth³, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada, ³Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Coronary atherosclerosis increases with age but is more prevalent in patients with systemic lupus erythematosus (SLE) independent of chronological age; this increased prevalence has…
Abstract Number: 1610 • 2017 ACR/ARHP Annual Meeting
The Impact of Alcohol Use on Cardiovascular Events and Overall Mortality in Women with Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Women with SLE have an increased risk of cardiovascular disease (CVD) and premature death. In the general population, moderate alcohol intake is associated with…
Abstract Number: 1611 • 2017 ACR/ARHP Annual Meeting
Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Yu Pei Chock¹, Abhijeet Danve¹, Wei Fu² and Michelle Petri³, ¹Rheumatology, Yale University, New Haven, CT, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Studies have indicated that increased body mass index (BMI) is a risk factor for development of Chronic Kidney Disease (CKD). Obesity is a low…
Abstract Number: 1612 • 2017 ACR/ARHP Annual Meeting
Primary Respiratory Disease in Patients with Systemic Lupus Erythematosus: Data from the Spanish Rheumatology Society Lupus Registry (RELESSER) Cohort
Javier Narváez¹, Helena Borrell², Fernando Sánchez-Alonso³, Iñigo Rúa-Figueroa⁴, Francisco Javier López Longo⁵, María Galindo⁶, Jaime Calvo-Alén⁷, Jose Luis Andreu⁸, Mariano Andres⁹, Juan José Alegre¹⁰, Ricardo Blanco¹¹, Tatiana Cobo-Ibáñez¹², Gema Bonilla¹³, Alina Boteanu¹⁴, Elvira Diez Alvarez¹⁵, Antonio Fernandez-Nebro¹⁶, Mercedes Freire¹⁷, Marian Gantes¹⁸, Paloma Garcia de la Peña¹⁹, Rosario García-Vicuña²⁰, José Hernández Beiraín²¹, Maria Loreto Horcada²², Jesus Ibañez²³, Antonio Juan²⁴, Nuria Lozano-Rivas²⁵, José Luis Marenco de la Fuente²⁶, Rafael-Benito Melero González²⁷, Carlos Alberto Montilla-Morales²⁸, Mireia Moreno²⁹, Alejandro Olivé³⁰, Maria Teresa Oton Sanchez³¹, Angela Pecondon-Español³², Esther Ruiz Lucea³³, Ana Sánchez Atrio³⁴, Gregorio Santos-Soler³⁵, Francisco Toyos³⁶, Esther Uriarte Isacelaya³⁷, Tomas Ramón Vazquez Rodriguez³⁸, Joan Miquel Nolla² and JM Pego-Reigosa³⁹, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁵Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Hospital de Sierrallana. Torrelavega. Cantabria. Spain, Alava, Spain, ⁸Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁹RHEUMATOLOGY, Hospital general universitario de Alicante, Alicante, Spain, ¹⁰Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, ¹¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁵Complejo Asistencial Universitario de León. León. Spain, León, Spain, ¹⁶Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, ¹⁷Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁸Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ¹⁹Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ²⁰Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²¹Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²²Rheumatology, Hospital de Navarra, Pamplona, Spain, ²³Rheumatology, Hospital Povisa, Vigo, Spain, ²⁴Rheumatology, Hospital Son LLatzer, Palma de Mallorca, Spain, ²⁵Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, ²⁶Rheumatology, Hospital de Valme, Seville, Spain, ²⁷Rheumatology, EOXI Vigo, Vigo, Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ³⁰Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ³¹Rheumatology Department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ³²Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ³³Rheumatology, Hospital de Basurto, Bilbao, Spain, ³⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ³⁵Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ³⁷Rheumatology, Hospital Universitario de Donosti, San Sebastian, Spain, ³⁸Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: To assess the prevalence, risk factors and impact on mortality of primary respiratory disease in a large retrospective cohort. Methods: All adult patients in…
Abstract Number: 1613 • 2017 ACR/ARHP Annual Meeting
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers
Noelle M. Teske¹, Khor Jia Ker^2,3, Rui Feng⁴, Benjamin F. Chong¹ and Victoria P Werth⁵, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Dermatology, National Skin Centre, Singapore, Singapore, ³Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: The natural disease course of patients with cutaneous lupus erythematosus (CLE) on standard-of-care treatments is not fully characterized. We sought to characterize their disease…
Abstract Number: 1614 • 2017 ACR/ARHP Annual Meeting
“Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend
Alexa Meara¹, Alexa Meara¹, Juliette Yedimenko², Juliette Yedimenko³, Holly Steigelman², Stacy P. Ardoin⁴ and Ellen Peters⁵, ¹Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Decision Research, Eugene, OR
Background/Purpose: Long-term SLE treatment is often complex due to changing clinical manifestations, disease fluctuation, and frequent medication changes. Treatment can be daunting especially to the…
Abstract Number: 1615 • 2017 ACR/ARHP Annual Meeting
Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus
Nicole Davidson¹, Alexa Meara², Holly Steigelman³, Songzhu Zhao⁴, Guy Brock⁵, Wael Jarjour⁶, Brad H. Rovin⁷, Samir parikh⁴, Hareth M. Madhoun⁸, Lee Hebert⁹, Isabelle Ayoub⁴ and Stacy P. Ardoin¹⁰, ¹The Ohio State University, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴The Ohio State University, Columbus, OH, ⁵Department of Biomedical Informatics and Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁷Ohio State University Medical Center, Columbus, OH, ⁸Rheumatology/Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁹Medicine, Ohio State University Medical Center, Columbus, OH, ¹⁰Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: : Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease which can impact the central nervous system in multiple ways, including development of cognitive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].